Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LAE102 in Healthy Subjects and Subjects with Overweight/Obesity

Next Previous
Search
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LAE102 in Healthy Subjects and Subjects with Overweight/Obesity

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LAE 102 (Primary) ; LAE 102 (Primary)
  • Indications Obesity
  • Focus Adverse reactions
  • Sponsors Laekna Therapeutics

    • Most Recent Events

    • 20 Nov 2024 According to Laekna, Inc media release, company announce a clinical collaboration with Eli Lilly and Company (Lilly), including diabetes and obesity, to accelerate the development of LAE102. Clinical development of LAE102 through phase 1 study including obese patients.
    • 20 Sep 2024 Status changed from not yet recruiting to recruiting.
    • 22 Jul 2024 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top